The effect of obesity pharmacotherapy on body composition, including muscle mass
The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Obesity pharmacotherapy represents a promising approach to treating obesity and may provide benefits beyond weight loss alone. Maintaining or even increasing muscle mass during weight loss is important to overall health, metabolic function and weight loss maintenance. Drugs such as liraglutide, semaglutide, tirzepatide, and naltrexone/bupropion have shown significant weight loss effects, and emerging evidence suggests they may also have effects on body composition, particularly a positive influence on muscle mass. However, further research is needed to fully understand the mechanism of action of these drugs and their effects on muscle mass. Clinicians should consider these factors when developing an obesity treatment plan for an individual patient.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, a more recent review evaluating the effects of obesity pharmacotherapy (including newer incretin-memetics) on body composition concludes that a non-significant percentage of muscle mass is lost, relative to fat mass (11).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [11]
In the citing paper
“Despite the efficacy of GLP‐1 receptor agonists in reducing body weight, limited data exist on their impact on body composition, including changes in fat mass, lean mass, muscle function, and the potential development of sarcopenia defined by a loss of muscle mass and function. 7”
From Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study (2026) · cites this paper as [7]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“Additionally, STEP 5 demonstrated that signi fi cant WL observed during 68 weeks of semaglutide treatment could be sustained with continued treatment for at least 104 weeks [41, 44].”
InfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 3×
“DUAL GLP-1/GIP RECEPTOR AGONISTS Tirzepatide is a once-weekly subcutaneous injectable medication, a dual agonist at both the GIP and GLP-1 receptors approved for both T2DM and obesity (FDA) that has recently entered the obesity pharmacotherapy fi eld [58, 59].”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×
“Recently, the SELECT trial demonstrated an impressive decline of cardiovascular risk by 20% in individuals without diabetes [40].”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 4×
“Body composition was not studied, although WC was reported reduced approximately 4.6 cm over placebo [22].”
InfluentialDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036 · cited 2×
“The COR studies as well as Light and Ignite studies showed a signi fi cant improvement in WC by circa 6.2 – 10.2 cm in patients assigned to the medication [65 – 67].”
InfluentialTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868 · cited 2×
“Additionally, STEP 5 demonstrated that signi fi cant WL observed during 68 weeks of semaglutide treatment could be sustained with continued treatment for at least 104 weeks [41, 44].”
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · cited 1×
“A signi fi cant reduction of WC was also seen in the SURMOUNT-4 trial, depicting a probable favorable effect in abdominal fat, a fi nding rather consistent in WL studies [63].”
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · cited 1×
“Concurrently, signi fi cant reductions in WC were observed ( − 4.7 cm in the intervention group vs. − 1.2 cm in the placebo group), highlighting liraglutide ’ s impact on abdominal fat [22, 23, 34, 35].”
Influentialon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Srikanthan, P., & Karlamangla, A. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0435 · Cited by 785 · cited 2×
“Skeletal muscle mass (SMM) relative to body weight shows an inverse association with insulin resistance, prediabetes, and diabetes risk, indicating increased protection against these conditions, particularly pronounced in individuals without diabetes [8].”
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693 · cited 1×
“…the available studies, a randomized double-blind controlled trial by Blundell et al. examining the impact of 1 mg sc semaglutide in individuals with obesity demonstrated a substantial reduction in mean body weight of 5.0 kg over 12 weeks, compared to a modest increase of + 1.0 kg with placebo [52].”
InfluentialGLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 1×
“…the favorable effects of liraglutide on white adipose tissue and preclinical indications of GLP-1 RAs activating brown adipose tissue (BAT), a randomized controlled trial (RCT) was conducted to investigate the impact of 1.8 mg of liraglutide on BAT in patients with type 2 diabetes (T2DM) [19, 20].”
InfluentialWadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513 · cited 1×
“Results showed that tirzepatide decreased liver fat content by an impressive 8.09% versus 3.38% in the insulin degludec group [64].”
InfluentialPreserving Healthy Muscle during Weight Loss
Cava, E., Yeat, N. C., & Mittendorfer, B. (2017) · Advances in Nutrition · doi:10.3945/an.116.014506 · Cited by 452 · cited 4×
“However, it appears that this is disproportionately less than FM reduction and without adversely affecting muscle strength [9, 11].”
InfluentialWadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407 · cited 1×
“The precise mechanism of tirzepatide is still a matter of ongoing research and it appears that GIP activation acts synergistically with GLP-1 receptor activation inducing WL via effects on hunger and satiety which consequently decrease energy intake [60].”
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397 · cited 1×
“When initial lifestyle interventions prove ineffective and anti-obesity drugs are prescribed, it is essential to persistently promote sustained lifestyle modi fi cations, ensuring not just WL but also the optimal preservation of MM [13].”
Heymsfield, S. B., Gonzalez, M. C. C., Shen, W., Redman, L., & Thomas, D. (2014) · Obesity Reviews · doi:10.1111/obr.12143 · Cited by 350 · cited 1×
“Notably, a threefold greater loss in mean fat over LBM was observed with semaglutide versus placebo, consistent with the established notion indicating an expected loss of approximately one-fourth FFM and the remaining three-fourths in FM among individuals with overweight and obesity [11, 53].”
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288 · cited 2×
“Subjects were randomly assigned to receive once-weekly sc semaglutide, titrated to a maximum dose of 2.4 mg per week, or placebo, alongside lifestyle intervention [42].”
InfluentialMcCrimmon, R. J., Catarig, A.-M., Frias, J. P., Lausvig, N. L., le Roux, C. W., Thielke, D., & Lingvay, I. (2020) · Diabetologia · doi:10.1007/s00125-019-05065-8 · Cited by 184 · cited 2×
“Semaglutide administration led to a reduction of 3.4 kg in total FM and a decrease of 2.3 kg in total LBM. Interestingly, the proportion of LBM increased by 1.2% with semaglutide [48].”
InfluentialDiets and drugs for weight loss and health in obesity – An update
Aaseth, J., Ellefsen, S., Alehagen, U., Sundfør, T. M., & Alexander, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111789 · Cited by 174 · cited 1×
“While various dietary patterns, when matched for caloric reduction, yield comparable effects on WL, the primary objective should be the predominant reduction of the excess FM due to its signi fi cant role in metabolic risk and poor physical function [10, 11].”
Effects of Weight Loss on Lean Mass, Strength, Bone, and Aerobic Capacity
WEISS, E. P., JORDAN, R. C., FRESE, E. M., ALBERT, S. G., & VILLAREAL, D. T. (2017) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001074 · Cited by 169 · cited 1×
“In order to achieve a favorable muscle to fat reduction ratio of approximately 1:3, it is crucial to include both aerobic and anaerobic exercises in a hypocaloric diet plan [11, 12].”
Weight loss strategies and the risk of skeletal muscle mass loss
McCarthy, D., & Berg, A. (2021) · Nutrients · doi:10.3390/nu13072473 · Cited by 163 · cited 4×
“Additionally, surpassing the recommended protein intake of 0.8 g/kg body weight/d may further help in stimulating muscle protein synthesis and minimizing muscle protein breakdown, especially when very low energy diets are followed, due to the rapid rate of WL [9].”
InfluentialTherakomen, V., Petchlorlian, A., & Lakananurak, N. (2020) · Scientific Reports · doi:10.1038/s41598-020-75250-y · Cited by 150 · cited 1×
“Considering the sustained preservation of MM associated with liraglutide treatment, a pertinent question arises regarding its safety in administration to older patients with obesity, who, due to their age are at a higher risk of sarcopenia [36].”
Gibbons, C., Blundell, J., Tetens Hoff, S., Dahl, K., Bauer, R., & Bækdal, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14255 · Cited by 149
Kooijman, S., Wang, Y., Parlevliet, E. T., Boon, M. R., Edelschaap, D., Snaterse, G., Pijl, H., Romijn, J. A., & Rensen, P. C. N. (2015) · Diabetologia · doi:10.1007/s00125-015-3727-0 · Cited by 140 · cited 1×
“…the favorable effects of liraglutide on white adipose tissue and preclinical indications of GLP-1 RAs activating brown adipose tissue (BAT), a randomized controlled trial (RCT) was conducted to investigate the impact of 1.8 mg of liraglutide on BAT in patients with type 2 diabetes (T2DM) [19, 20].”
InfluentialFeng, W., Bi, Y., Li, P., Yin, T., Gao, C., Shen, S., Gao, L., Yang, D., & Zhu, D. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12888 · Cited by 139 · cited 2×
“…in individuals with overweight, T2DM, non-alcoholic fatty liver disease (NAFLD), and high cardiovascular risk showed that participants in the liraglutide group (in the daily dose of 1.8 mg) witnessed a substantial reduction in body weight (from 81.1 ± 2.3 kg to 75.5 ± 2.0 kg, P 0.01) [31].”
InfluentialNovel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A., Koliaki, C. C., & Mantzoros, C. S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 128 · cited 1×
“It is associated with various comorbidities and thus effective pharmacotherapy is essential in an attempt to prevent accompanying complications [3].”
Self-citationPerna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125 · cited 1×
“Taking into consideration that the study included, as stated above, inactive individuals, this fi nding could suggest that liraglutide contributes to the maintenance of trophic SMM preventing muscle protein breakdown [29].”
Wilding, J. P. H., Batterham, R. L., Calanna, S., Van Gaal, L. F., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wharton, S., Yokote, K., Zeuthen, N., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab048.030 · Cited by 107 · cited 3×
“To determine if WL primarily resulted from fat loss rather than LBM, a subgroup in STEP 1 with a BMI of ≤ 40 kg/m 2 underwent assessment of body composition via DEXA [45].”
GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
Xiang, J., Qin, L., Zhong, J., Xia, N., & Liang, Y. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s425642 · Cited by 100 · cited 3×
“The effect of both GLP-1RA liraglutide and semaglutide on obesity-induced muscle atrophy has been shown in mice where it reduced high fat diet-induced body weight gain while improving muscle atrophy, signi fi cantly reducing MM loss accompanying the robust WL effect seen after the intervention [17].”
InfluentialSubaran, S. C., Sauder, M. A., Chai, W., Jahn, L. A., Fowler, D. E., Aylor, K. W., Basu, A., & Liu, Z. (2014) · Clinical Science · doi:10.1042/cs20130708 · Cited by 95 · cited 1×
“Likewise, a study in humans wherein a GLP-1 RA was acutely infused intravenously, was associated with improved skeletal muscle microvasculature, suggesting that GLP-1 agonists may have a positive effect on muscle [18].”
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., San Jose, P., Rubio, M. Á., & Lecube, A. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s223618 · Cited by 88 · cited 1×
“Shifting the focus to patients with T1DM, there has been an increasing prevalence of overweight and obesity among them in recent years [37].”
Li, C.-J., Yu, Q., Yu, P., Yu, T.-L., Zhang, Q.-M., Lu, S., & Yu, D.-M. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-36 · Cited by 86
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., et al. (2022) · Nutrients · doi:10.3390/nu14214673 · Cited by 84 · cited 1×
“Furthermore, liver steatosis showed improvement in a substantial majority of patients (70%), with a reduction by at least one class according to the semiquantitative ultrasound staging [49].”
Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents
Gurjar, A. A., Kushwaha, S., Chattopadhyay, S., Das, N., Pal, S., China, S. P., Kumar, H., Trivedi, A. K., Guha, R., Chattopadhyay, N., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154044 · Cited by 79 · cited 1×
“Studies in animal models have revealed that liraglutide induces myogenesis in myoblasts and may protect against muscular atrophy, restoring myo fi brillar architecture [16].”
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Triggiani, V., Sabbà, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240263 · Cited by 73 · cited 3×
“The oral form of semaglutide has also been studied and results on body composition have been reported by studies in populations with T2DM, titrated up to the indicated dose of 14 mg [50, 51, 54, 55].”
Hughes, S., & Neumiller, J. J. (2020) · Clinical Diabetes · doi:10.2337/cd19-0079 · Cited by 63 · cited 1×
“…with the previously mentioned alterations, and given that oral administration does not seem to compromise the glucose-or weight-lowering ef fi cacy of the active substance, as evidenced in the PIONEER 4 study, similar outcomes could be anticipated in individuals with obesity on higher doses [56].”
FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade
Idrees, Z., Cancarevic, I., & Huang, L. (2022) · Cureus · doi:10.7759/cureus.29262 · Cited by 63 · cited 3×
“Semaglutide, another GLP-1 receptor agonist, is an antidiabetic and anti-obesity medication used for the treatment of T2DM as well as for long-term weight management [24].”
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity
Smith, S. R., Fujioka, K., Gupta, A. K., Billes, S. K., Burns, C., Kim, D., Dunayevich, E., & Greenway, F. L. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12095 · Cited by 55
van Eyk, H. J., Paiman, E. H. M., Bizino, M. B., IJzermans, S. L., Kleiburg, F., Boers, T. G. W., Rappel, E. J., Burakiewicz, J., Kan, H. E., Smit, J. W. A., et al. (2020) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.12.005 · Cited by 54 · cited 1×
“…and activation, the trial revealed that liraglutide treatment led to a reduction in the supraclavicular BAT compared to placebo, suggesting that the liraglutide-induced WL may be attributed more to a decrease in energy intake rather than an increase in resting energy expenditure (REE) [21].”
FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management
Abbasi, J. (2023) · JAMA · doi:10.1001/jama.2023.24539 · Cited by 54 · cited 1×
“DUAL GLP-1/GIP RECEPTOR AGONISTS Tirzepatide is a once-weekly subcutaneous injectable medication, a dual agonist at both the GIP and GLP-1 receptors approved for both T2DM and obesity (FDA) that has recently entered the obesity pharmacotherapy fi eld [58, 59].”
Ozeki, Y., Masaki, T., Kamata, A., Miyamoto, S., Yoshida, Y., Okamoto, M., Gotoh, K., & Shibata, H. (2022) · Medicines · doi:10.3390/medicines9090047 · Cited by 53 · cited 2×
“The oral form of semaglutide has also been studied and results on body composition have been reported by studies in populations with T2DM, titrated up to the indicated dose of 14 mg [50, 51, 54, 55].”
Uchiyama, S., Sada, Y., Mihara, S., Sasaki, Y., Sone, M., & Tanaka, Y. (2023) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4987 · Cited by 52 · cited 3×
“The oral form of semaglutide has also been studied and results on body composition have been reported by studies in populations with T2DM, titrated up to the indicated dose of 14 mg [50, 51, 54, 55].”
Perna, S., Rondanelli, M., Astrone, P., Grugnetti, A., Solerte, S. B., & Guido, D. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s97383 · Cited by 42 · cited 3×
“…for various confounding factors (age, sex, duration of diabetes), the study revealed signi fi cant reductions in BMI ( − 0.86 kg/m 2 ), FM ( − 2.01 kg), fat mass index ( − 0.71 kg/m 2 ), android fat ( − 1.72%), trunk fat ( − 1.52%), and WC ( − 6.86 cm), compared to the baseline values [30].”
InfluentialIshii, S., Nagai, Y., Sada, Y., Fukuda, H., Nakamura, Y., Matsuba, R., Nakagawa, T., Kato, H., & Tanaka, Y. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3647 · Cited by 41 · cited 3×
“…with the decline in serum alanine aminotransferase and aspartate aminotransferase levels [31], while another study in a population with overweight or obesity and T2DM revealed a mean reduction of 49.2% in intrahepatic lipid content assessed by proton magnetic resonance spectroscopy [26].”
InfluentialWadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., Aronne, L., & on behalf of the NN8022-1923 Investigators (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.88 · Cited by 40
Dubé, M., D'Amours, M., & Weisnagel, S. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13063 · Cited by 38 · cited 1×
“…involving liraglutide, with a maintenance dose of 1.8 mg daily, have demonstrated noteworthy reductions in various body composition measures, including weight, BMI, waist and hip circumferences, body fatness, and computed tomography (CT) scan measurements of the abdomen and mid-thigh [38].”
Influential(2023) · doi:10.26355/eurrev_202310_34169 · Cited by 36 · cited 1×
“Another study by Xiang et al., focusing on the same semaglutide dose combined with lifestyle interventions over 24 weeks in a Chinese adult population with obesity, reported a signi fi cant WL while observing a slight, though not statistically signi fi cant, decrease in MM and muscle strength [46].”
Janssen, T. A. H., Van Every, D. W., & Phillips, S. M. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000980 · Cited by 33 · cited 1×
“Abrupt declines in MM may result in decrease of muscle strength, making endurance exercise an important constituent of WL programs [5, 6].”
Clapper, J. R., Athanacio, J., Wittmer, C., Griffin, P. S., D’Souza, L. J., Parkes, D. G., & Roth, J. D. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.010 · Cited by 32 · cited 1×
“In contrast, combining amylin with N/B resulted in greater fat loss, while signi fi cantly increasing the percentage of total LBM [69].”
Kim, B., Tsujimoto, T., So, R., Zhao, X., Oh, S., & Tanaka, K. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s132707 · Cited by 32 · cited 1×
“Abrupt declines in MM may result in decrease of muscle strength, making endurance exercise an important constituent of WL programs [5, 6].”
Schmidt, S., Frandsen, C. S., Dejgaard, T. F., Vistisen, D., Halldórsson, T., Olsen, S. F., Jensen, J. B., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14567 · Cited by 29 · cited 1×
“In terms of the differential impact on body compartments, the reduction in total body FM appears to be approximately double that of LBM in participants who have both overweight and insulin pump-treated T1DM treated with 1.8 mg/ day liraglutide (FM − 4.6 kg, P < 0.001; LBM − 2.5 kg, P < 0.001) [39].”
InfluentialLiraglutide Does Not Adversely Impact Fat‐Free Mass Loss
Grannell, A., Martin, W. P., Dehestani, B., Al‐Najim, W., Murphy, J. C., & le Roux, C. W. (2021) · Obesity · doi:10.1002/oby.23098 · Cited by 28 · cited 1×
“Hence, to counteract the decline in FFM following liraglutide, a novel strategy combining exercise with targeted nutritional interventions, such as a more pronounced increase in protein intake during WL periods may be warranted [27].”
Revisiting Resting Metabolic Rate: What is the Relation to Weight Fluctuations?
Argyrakopoulou, G., Fountouli, N., Dalamaga, Μ., & Kokkinos, A. D. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00528-x · Cited by 28 · cited 1×
“The main tissue involved in energy expenditure is fat-free mass (FFM), as opposed to FM, which exerts a substantially lower impact [7].”
Self-citationYu, D., Zou, M., Pan, Q., Song, Y., Li, M., Zhang, X., Zhou, Y., Wang, X., & Guo, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.951570 · Cited by 24 · cited 3×
“…exhibited, in addition to the more signi fi cant changes in hemoglobin A1c (HbA1c) levels, improvements in visceral fat area, and subcutaneous fat area of the abdomen, indicating liraglutide as a preferred option for glucose weight management and reduction of abdominal fat in this population [32].”
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 22 · cited 1×
“Liraglutide, naltrexone/bupro-pion and newer drugs i.e., semaglutide and tirzepatide are emerging as very promising options not only for weight loss (WL) per se [4], but also because of their potential positive effects on body composition, including muscle mass (MM).”
Self-citationPownall, H. J., Schwartz, A. V., Bray, G. A., Berkowitz, R. I., Lewis, C. E., Boyko, E. J., Jakicic, J. M., Chen, H., Heshka, S., Gregg, E. W., et al. (2016) · Obesity · doi:10.1002/oby.21577 · Cited by 21 · cited 1×
“This improvement in body composition was also illustrated in the ratio of FM loss to LBM loss, an effect similar to lifestyle and surgical interventions [61].”
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
O’Neil, P. M., & Rubino, D. M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2150006 · Cited by 19 · cited 1×
“STEP trials 1, 2, 4, and 5 involved daily recommendations of a 500-calorie reduction and 150 min of physical activity, while STEP 3 encouraged intensive behavioral therapy with a low-calorie diet [43].”
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16 · cited 1×
“Liraglutide and semaglutide are both glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) that have attracted attention for their dual effects of promoting WL and improving glycemic control [14, 15].”
Self-citationStefanakis, K., Kokkinos, A. D., Simati, S., Argyrakopoulou, G., Konstantinidou, S. M., Kouvari, M., Kumar, A., Kalra, B., & Mantzoros, C. S. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.06.026 · Cited by 14 · cited 2×
“Liraglutide and semaglutide are both glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) that have attracted attention for their dual effects of promoting WL and improving glycemic control [14, 15].”
Self-citationTu1921 - Liraglutide Treatment Modulates Regional Body Fat Distribution in Individuals with Obesity
Kadouh, H. C., Halawi, H., Chedid, V. G., Khemani, D., Burton, D. B., Eckert, D. J., Clark, M., Grothe, K. B., Acosta, A. J., Vella, A. V., et al. (2018) · Gastroenterology · doi:10.1016/s0016-5085(18)33527-3 · Cited by 3 · cited 2×
“[33].”
Research works printed but not linked: 2
- Konwar M, Bose D, Jaiswal SK, Maurya MK, Ravi R. Efficacy and safety of liraglutide 3.0 mg in patients with overweight and obese with or without diabetes: a systematic review and meta-analysis. Int J Clin Pr. 2022;2022:1201977.
- Keskin L, Yaprak B. Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus. Eur Rev Med Pharm Sci. 2022;26:6813–20.
Cited by
Alissou, M., Demangeat, T., Folope, V., Van Elslande, H., Lelandais, H., Blanchemaison, J., Cailleaux, P., Guney, S., Aupetit, A., Aubourg, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70141 · Cited by 72
“7 Current data suggest a preservation of muscle mass and function during Semaglutide treatment.”
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 57
Beavers, K. M., Cortes, T. M., Foy, C. M., Dinkla, L., Reyes San Martin, F., Ard, J. D., Serra, M. C., & Beavers, D. P. (2025) · Obesity · doi:10.1002/oby.24172 · Cited by 41
“In contrast, a more recent review evaluating the effects of obesity pharmacotherapy, including newer incretin-memetics, on body composition concludes that a nonsignificant percentage of muscle mass is lost relative to fat mass (FM) [11].”
Physiology of Weight Regain after Weight Loss: Latest Insights
van Baak, M. A., & Mariman, E. C. M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00619-x · Cited by 40
“Moreover, most of these studies are associative, whereas unravelling the the newer anti-obesity medications [35–38].”
Chao, C., Kovesdy, C. P., & Merchant, R. A. (2025) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.24.207 · Cited by 37
“GLP-1 receptor agonists modulate appetite and satiety and shown to increase lean body mass and muscle strength [40].”
Metadata
- Authors
- Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A.
- Affiliations
- Athens Medical Center (GR)
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Argyrakopoulou, Georgia
- Venue
- International Journal of Obesity
- Published
- 2024-05-14
- Volume
- 49
- Issue
- 3
- Pages
- 381-387
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W4396904658
- Cited by
- 28
- References
- 68
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 2
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity pharmacotherapy, body composition, muscle mass, weight loss, liraglutide, semaglutide, tirzepatide, naltrexone/bupropion, weight loss maintenance, GLP-1 receptor agonists, appetite suppressants
- MeSH terms
- Liraglutide, Body Composition, Humans, Naltrexone, Obesity, Weight Loss, Muscle, Skeletal, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.